Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive

Derek J Essegian1,2, Tyler A Cunningham1,2, Christopher J Zerio3

  • 1Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida 33136, United States.

ACS Omega
|October 4, 2021
PubMed

Insights

Researchers identified a novel phenyl-piperazine compound targeting the ATP-binding site of eukaryotic initiation factor 4A1 (eIF4A1), a key protein in cancer development. This discovery offers a new avenue for developing targeted cancer therapies.

Area of Science:

  • Biochemistry and Molecular Biology
  • Structural Biology
  • Drug Discovery

Background:

  • Eukaryotic initiation factor 4A1 (eIF4A1) is an ATP-dependent RNA helicase implicated in oncogenesis.
  • Understanding eIF4A1's complex kinetics and conformational changes is crucial for developing targeted inhibitors.

Purpose of the Study:

  • To quantitatively analyze eIF4A1 conformational changes.
  • To discover novel, chemically tractable inhibitors targeting eIF4A1.

Main Methods:

  • Protein-ligand docking
  • Homology modeling
  • Extended molecular dynamics simulations

Main Results:

  • Discovery of a novel phenyl-piperazine pharmacophore.
  • Predicted binding to the ATP-binding site of eIF4A1.
  • Identification of an ATP-competitive inhibitor targeting the nucleotide cleft.

Conclusions:

  • The identified pharmacophore is the first reported ATP-competitive inhibitor for eIF4A1.
  • The interdisciplinary pipeline provides a framework for future drug discovery targeting eIF4A1 and similar proteins.

Related Concept Videos